538 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
SNY Sanofi $43.75 $109.14B N/A
Article Searches
Why Biotech ETFs are Surging to New Highs http://www.zacks.com/stock/news/664321/why-biotech-etfs-are-surging-to-new-highs?cid=CS-ZC-FT-etf_news_and_commentary-664321 Dec 10, 2019 - increasing M&A deals and cutting edge therapies are driving biotech ETFs higher
Sanofi Is Paying a 172% Premium to Buy Synthorx -- and It Sounds Like a Good Deal for Both https://www.fool.com/investing/2019/12/10/sanofi-is-paying-a-172-premium-to-buy-synthorx-and.aspx?source=iedfolrf0000001 Dec 10, 2019 - Sanofi, with sales falling in its older businesses, boosts its higher-growth immuno-oncology business with the $2.5 billion purchase of Synthorx.
Biotech ETFs Hit New Highs on Deal Activities http://www.zacks.com/stock/news/663878/biotech-etfs-hit-new-highs-on-deal-activities?cid=CS-ZC-FT-etf_news_and_commentary-663878 Dec 10, 2019 - Following the new deals in the healthcare space, a few biotech ETFs hit new highs.
Merck to Buy ArQule for $2.7B to Boost Cancer Portfolio http://www.zacks.com/stock/news/663844/merck-to-buy-arqule-for-%2427b-to-boost-cancer-portfolio?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-663844 Dec 10, 2019 - Merck (MRK) offers to acquire ArQule for a deal value of $2.7 billion. The transaction will add ArQule's lead investigational candidate ARQ 531 to Merck's oncology portfolio.
Sanofi Unveils Growth Strategy, Ends Diabetes & CV Research http://www.zacks.com/stock/news/663717/sanofi-unveils-growth-strategy-ends-diabetes-cv-research?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-663717 Dec 10, 2019 - Sanofi (SNY) to prioritize key growth drivers, improve operating efficiencies and generate cost savings. The company discontinues R&D activities in diabetes and cardiovascular segments.
Pharma M&As Continue, Merck, Sanofi to Buy Cancer Drug Firms http://www.zacks.com/stock/news/663641/pharma-mas-continue-merck-sanofi-to-buy-cancer-drug-firms?cid=CS-ZC-FT-analyst_blog|industry_focus-663641 Dec 10, 2019 - Merck offers to buy ArQule for $2.7 billion while Sanofi signs a definitive deal to purchase Synthorx for $2.5 billion.
Sanofi to Buy Synthorx for $2.5B to Boost Cancer Portfolio http://www.zacks.com/stock/news/662014/sanofi-to-buy-synthorx-for-%2425b-to-boost-cancer-portfolio?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-662014 Dec 09, 2019 - Sanofi (SNY) offers to buy Synthorx (THOR) for $2.5 billion. The deal will add Synthorx's lead pipeline asset, THOR-707 to Sanofi's oncology portfolio.
Regeneron Reports Positive Data on Rare Blood Disorder Drug http://www.zacks.com/stock/news/657613/regeneron-reports-positive-data-on-rare-blood-disorder-drug?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-657613 Dec 06, 2019 - Regeneron (REGN) announces positive top-line data from a phase II study on rare blood disorder drug.
Alnylam Gets Second Product Approval Amid Stiff Competition http://www.zacks.com/stock/news/646584/alnylam-gets-second-product-approval-amid-stiff-competition?cid=CS-ZC-FT-analyst_blog|zer_report_update-646584 Nov 29, 2019 - Alnylam (ALNY) gets FDA approval for givosiran injection for subcutaneous use to treat adults with acute hepatic porphyria. Givosiran injection will be marketed by the trade name of Givlaari.
Novartis (NVS) to Acquire The Medicines Company for $9.7B http://www.zacks.com/stock/news/636880/novartis-nvs-to-acquire-the-medicines-company-for-%2497b?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-636880 Nov 25, 2019 - Novartis (NVS) set to acquire The Medicines Company and add a promising candidate to its cardiovascular pipeline.

Pages: 12345678910...54

<<<Page 5>